Clinical Trial Update: Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer [Phase 1]

View source ↗

Summary

Phase I study of MLN0128 and MLN8237 in patients with advanced solid tumors and metastatic triple-negative breast cancer completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Solid Tumors

Drugs mentioned

• MLN0128 (sapanisertib)
• MLN8237 (alisertib)

Snippet

Sponsor: University of Colorado, Denver | Conditions: Metastatic Breast Cancer, Solid Tumors | Phase 1 | Status: COMPLETED | Results posted: 2022-01-19